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Acute lung injury (ALI) and acute respiratory distress syn-
drome (ARDS) are important causes of morbidity and mortal-
ity. In the United States, the estimated incidence of ALI is
190,600 cases per year with an in-hospital mortality rate of
nearly 40%.1 Little is known about the incidence of viral
infection in adults with ALI. A study of 592 children in Italy
with community-acquired pneumonia, without specification
of ALI, found that 74% of the enrolled children had a viral
infection by direct fluorescent antigen (DFA) or polymerase
chain reaction (PCR).2 In clinical practice, viral infections are
diagnosed using DFA assays, PCR-based assays, and viral
culture. These methods only assess the most well-known
human pathogens, including influenza A and B, parain-
fluenza, respiratory syncytial virus (RSV), adenovirus, meta-
pneumovirus, rhinovirus, enterovirus, coronavirus, and
cytomegalovirus (CMV). Research laboratories have the abili-
ty to detect many more viruses with nucleic acid amplifica-
tion methods, although the clinical significance of these
viruses is not well understood. This review focuses on the
twoviruses that causedmajor respiratory illness epidemics in
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Abstract Acute viral pneumonia is an important cause of acute lung injury (ALI), although not
enough is known about the exact incidence of viral infection in ALI. Polymerase chain
reaction-based assays, direct fluorescent antigen (DFA) assays, and viral cultures can
detect viruses in samples from the human respiratory tract, but the presence of the virus
does not prove it to be a pathogen, nor does it give information regarding the
interaction of viruses with the host immune response and bacterial flora of the
respiratory tract. The severe acute respiratory syndrome (SARS) epidemic and the
2009 H1N1 influenza pandemic provided a better understanding of how viral pathogens
mediate lung injury. Although the viruses initially infect the respiratory epithelium, the
relative role of epithelial damage and endothelial dysfunction has not been well defined.
The inflammatory host immune response to H1N1 infection is a major contributor to
lung injury. The SARS coronavirus causes lung injury and inflammation in part through
actions on the nonclassical renin angiotensin pathway. The lessons learned from the
pandemic outbreaks of SARS coronavirus and H1N1 capture key principles of virally
mediated ALI. There are pathogen-specific pathways underlying virally mediated ALI
that converge onto a common end pathway resulting in diffuse alveolar damage. In
terms of therapy, lung protective ventilation is the cornerstone of supportive care. There
is little evidence that corticosteroids are beneficial, and they might be harmful. Future
therapeutic strategies may be targeted to specific pathogens, the pathogenetic path-
ways in the host immune response, or enhancing repair and regeneration of tissue
damage.
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the last decade: severe acute respiratory syndrome coronavi-
rus (SARS CoV) and the 2009 pandemic H1N1 influenza A
virus. In the years following these outbreaks, research using
animal models elucidated some of the mechanisms involved
in virally mediated ALI. Investigations into other common
viral pathogens have also reshaped the way we think about
the role of viral infection in ALI. For example, CMV is a
common pathogen in severely immunosuppressed popula-
tions (especially organ transplant recipients), but was previ-
ously thought to be an uncommon pathogen in nosocomial
pneumonia. With new diagnostic tools, the importance of
detection, prevention, and treatment of CMV pneumonia in a
broader population of critically ill patients is being reconsid-
ered. Seroprevalence for CMV in adults ranges from 50 to 90%.
CMV has been detected in nonimmunocompromised adults
with critical illness and is thought to be reactivation of latent
infection. It is associatedwith longer intensive care unit (ICU)
and hospital stays, longer duration of mechanical ventilation,
and increased rates of nosocomial infections. CMV infection is
associated with increased interleukin (IL)-6 and IL-8 in vitro
and invivo, and these cytokines havebeen associatedwith ALI
and ARDS.3 Autopsy studies suggest that CMV may be an
important pathogen in ventilator-associated pneumonia
(VAP).4 These observations provide the rationale for a pro-
spective, randomized trial of CMV prevention with an antivi-
ral agent such as ganciclovir as a novel means of improving
outcomes in critically ill patients. In the era of sensitive and
rapid nucleic acid amplification diagnostic tests, we can
detect the presence of infectious agents, but determining
when particular viruses are pathogenic and how they interact
with the host immune system to cause lung injury or resolu-
tion of infection is an area of active research. It will be
important to gain a better understanding of molecular patho-
physiology of community-acquired and nosocomial viral
pneumonias to devise more targeted therapies because cur-
rent treatments are largely supportive.
The underlying pathophysiology of virally mediated ALI is
not well understood, and it is likely that there are unique
signature mechanisms to each viral strain that converge onto
a common end pathway resulting in diffuse alveolar damage
(DAD). It remains to be seen whether epithelial injury is the
primary lesion or is coincident to endothelial injury. Most
community-acquired respiratory viral pneumonias are in-
haled and bind to receptors in the upper respiratory tract.
Although the viruses initially infect the respiratory epitheli-
um, it is possible that this is merely a portal of entry, and the
important steps in alveolar damage aremediated primarily by
endothelial injury resulting in elaboration of cytokines and
chemokines and recruitment of both innate and adaptive
immune cells. The specific cytokine profiles vary by viral
pathogen andmay be driven bymacrophages, epithelial cells,
endothelial cells, or some combination of crosstalk. If lung
injury is not primarily mediated by viral infection, but rather
is a result of the inflammatory host response, then viral
clearance may not be central to the resolution of lung injury.
The lessons learned from studying pandemic outbreaks of
SARS CoV and H1N1 infection are reviewed in this article.
Background and Epidemiology of Severe
Acute Respiratory Syndrome
In February 2003 an outbreak of SARSwas first reported in the
Guangdong province of China. Patients presented with fever,
lower respiratory tract symptoms, and infiltrates on chest
radiography consistent with pneumonia or ARDS. Within
1 month, cases were reported in Hong Kong, Singapore, Viet-
nam, and Canada, and the World Health Organization (WHO)
launched efforts to investigate the illness and contain the rapid
spread. The index case was a physician from Guandong prov-
ince who had traveled to Hong Kong 5 days after symptom
onset. The illness rapidly spread to more than two dozen
countries in North America, South America, Europe, and Asia
before the SARS global outbreak of 2003was contained (http://
www.who.int/csr/sars/en/). In April 2003, the causative agent
was identified as a newmember of the orderNidovirale and the
coronavirus family (Coronaviridae).5 The SARS CoV is an envel-
oped RNA virus that replicates with transcription of discontin-
uous nested messenger RNA (mRNA). The reservoir for the
virus is thought to be civet cats, a nocturnal mammal consid-
ered a delicacy in southern China. Horseshoebatsmay also be a
reservoir. The incubation period is 2 to 7 days before symptom
onset, and peak viral shedding in respiratory secretions occurs
relatively late, between 6 and 11 days. The virus is spread
through respiratory secretion shedding and via contact with
fomites. Airborne transmission, particularly on international
flights, contributed to superspreader outbreak phenomenon.
By July 2003 there were 8,096 cases reported and 774 deaths
due to SARSCoV, yielding a case fatality rate of 9.6%. In July 2003
the WHO lifted the travel advisory and the outbreak of SARS
ended. Later in 2003 and 2004, there were four small SARS
outbreaks. Three of these were laboratory-based outbreaks;
one was attributed to exposure to an infected palm civet.
Several epidemiological studies using logistic regression
showed that older age and underlying comorbid conditions
(diabetes, chronic obstructive pulmonary disease, hepatitis B
infection, cancer, and cardiac disease) were associated with
worse outcomes including ICU admission, mechanical venti-
lation, and death.6,7 The estimated case fatality ratewas 13.2%
(9.8 to 16.8) for patients younger than 60 years and 43.3%
(35.2 to 52.4) for patients aged 60 years or older assuming a
parametric gamma distribution.8,9 The characteristics of
patients most susceptible to infection are fairly nonspecific
and provided limited insight into themechanism of ALI that is
mediated by SARS CoV infection. There has been some
speculation that the severity of infection in older individuals
is related to oxidative-stress machinery and an increased
innate immunity response and more robust inflammatory
response in older individuals. Agedmacaques have a stronger
host response to viral infection and show an increase in
differential expression of genes associated with inflamma-
tion. Specifically nuclear factor kappa B (NF-kB) expression
was upregulated, and type I interferon (IFN) was downregu-
lated in older macaques andwas associated with more severe
lung injury.10 The clinical pathology of patients who die with
SARS infection cannot easily distinguish SARS-mediated ALI
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from other types of lung injury and ARDS. Early reports from
SARS case fatalities from Nan Fang Hospital Guangdong,
China, showed pulmonary lesions that included DAD with
hyaline membrane formation. Local hemorrhage and necro-
sis, desquamative pulmonary alveolitis and bronchitis, pro-
liferation and desquamation of alveolar epithelial cells,
exudation of protein and monocytes, lymphocytes and plas-
ma cells in alveoli, hyaline membrane formation, and viral
inclusion bodies in alveolar epithelial cells were also ob-
served. Electron microscopy demonstrated clusters of viral
particles, consistent with CoV, in lung tissue.11 In 2005 a case
control series from the University of Toronto described
postmortem studies of pathology specimens from 20 patients
who died betweenMarch and July 2003with SARS confirmed
by reverse transcription (RT)-PCR. The authors compared
these patients to 22 age- and gender-matched SARS CoV–
negative patients who presented with lower respiratory tract
signs and symptoms and died during the same time period.
The SARS patients had a longer mean duration of illness than
controls and were more likely to have evidence of organizing
pneumonia on hematoxylin and eosin–stained slides. All of
the SARS cases exhibited pathological evidence of DAD,
whereas 50% of controls had evidence of DAD. The authors
reported significant overlap between SARS and non-SARS
cases of patients who died with ARDS. They noted that it is
difficult, if not impossible, to differentiate alveolar damage
from SARS infection from other etiologies.12 Overall, these
findings suggest that the mechanism of ALI initiated by SARS
CoV infection has a commonpathwaywith othermechanisms
that result in DAD and organizing pneumonia.
Treatment Recommendations Based on
Human Studies
The outbreak of SARS infection was brief thanks to the
effective containment efforts orchestrated by WHO and the
Centers for Disease Control and Prevention (CDC) with the
cooperation of governments of affected countries. The short-
lived outbreak of SARS CoV infection provided little time for
studying effective therapies. As in most cases of ALI, treat-
ment of SARS is largely supportive; there is no known
effective targeted therapy, and there is no clear role for
corticosteroids. Limited in vitro and clinical trial data from
ARDS studies exists for treatment with ribavirin, cortico-
steroids, lopinavir and ritonavir (LPV/r), type I IFN, intrave-
nous immunoglobulin (IVIG), and SARS convalescent plasma.
A systematic review of the literature sponsored by WHO
reported that SARS CoV infection in tissue culture models
was inhibited by ribavirin, lopinavir, and type I IFN. However,
in SARS-infected patient reports on ribavirin, most studies
were inconclusive, and four showed possible harm. Seven
studies of convalescent plasma or IVIG, three of IFN type I,
and two of LPV/r were inconclusive. In 29 studies of steroid
use, 25 were inconclusive and 4 were classified as causing
possible harm.13 There have been no cases of SARS reported
since 2004. Although the best care strategy for infected
individuals is still unclear, the virus provided an opportunity
to study pathways involved in ALI that may be common in
lung injury mediated by other infectious agents or systemic
illnesses.
Experimental Animal Models of SARS
Infection
The membrane-bound Spike glycoprotein is critical for re-
ceptor binding andmembrane fusion of the virus to host cells.
In 2003, Li et al14 published data from immunoprecipitation
experiments and mass spectroscopy that identified a novel
protein, angiotensin-converting enzyme 2 (ACE2) as the
binding target for the Spike protein on the SARS CoV virus.
ACE2 is an integral membrane metallopeptidase that cleaves
angiotensin II (ATII) to form angiotensin 1–7 (Ang 1–7).
Binding of SARS CoV to the ACE2 receptor causes internaliza-
tion of the virus and downregulation of ACE2 expression. This
discovery led to extensive investigation into the role of ACE2
in animal ALI models.
The tissue tropism of SARS CoV correlates with ACE2
expression and includes the lung, gastrointestinal tract, kid-
ney, and liver. In humans, ACE2 protein has been detected
throughout the respiratory tree, including in the epithelial
cells of alveoli, trachea, bronchi, bronchial serous glands, as
well as pneumocytes, and alveolar monocytes and macro-
phages.11 Because ACE2 is expressed in the alveolar epitheli-
um in both type I and type II alveolar epithelial cells and in the
vascular endothelium of the lung in humans, it seems that the
initial binding of the virus is in the respiratory tract, but
progression of severe illness and lung injury involves endo-
thelial pathology aswell.15Although the C-type lectin CD209L
(also known L-SIGN), and dendritic cell-specific C-type lectin
bind SARS CoV, ACE2 appears to be the key functional
receptor for the virus.16
ACE2 plays a central role in the nonclassical renin angio-
tensin system (RAS). The activity of classical and nonclassical
RAS pathways appears to be balanced under normal physio-
logical conditions. However, in several ALI models activation
of AT II by ACE increases signaling through angiotensin Ia
receptor (AT1aR), and ACE2 activity is downregulated. ACE2 is
a negative regulator of the ACE pathway and cleaves AT II to
formAng 1–7 (►Fig. 1). The downstream effects of Ang 1–7 in
the kidney are mediated by the G protein-coupled receptor,
Mas, which appears to be an antagonist of the AT1aR.17 ACE2
is necessary for the SARS CoV virus to infect alveolar epithelial
cells in mice. SARS CoV-infected cells express proinflamma-
tory cytokines including IL-6, IL-8, transforming growth
factor (TGF) α and β, and monocyte chemotactic protein I
(MCP-1). Some data suggest that a lack of type 1 IFN response
may be important in SARS CoV–mediated lung injury.16
Administration of type I IFN in aged macaques infected
with SARS CoV reduced lung injury.10 A variety of ALI animal
models suggest that increased signaling through ACE and its
downstream cytokines and decreased signaling through
ACE2 may be important for lung injury.
In 2005, Imai et al18 published findings from a series of
murine knockout and rescue experiments that showed AT II is
upregulated by ACE and drives ALI through AT1aR and that
ACE2 and angiotensin II receptor 2 protect against lung injury
Seminars in Respiratory and Critical Care Medicine Vol. 34 No. 4/2013
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in aspiration and sepsis models. The authors showed that loss
of ACE2 expression precipitates severe acute lung failure in
three separate ALImodels. Lung injury in ACE2 knockoutmice
resulted in increase elastance and worsened hypoxemia
compared with wild-type mice subjected to acid aspiration
lung injury. The ACE2 knockout lung injury phenotype is
rescued by intraperitoneal administration of recombinant
human ACE2 protein. ACE knockout is protective against
lung injury in a gene dose-dependent fashion with the
heterozygote showing an intermediate reduction of lung
compliance after acid-induced lung injury as compared
with the wild-type and ACE knockout. ACE knockout rescues
ACE2 knockout lung injury in a gene dose-dependent fashion
and results in improved lung compliance and reduction of
pulmonary edema seen in ACE2 knockout mice with acid
aspiration lung injury. AT1 receptor blockade rescues ACE2
knockout lung injury. An AT1aR antagonist ameliorates lung
injury in wild-type mice with acid aspiration lung injury.
Similar results have been reported for bleomycin-induced
lung injury models. ACE2 knockout worsened bleomycin-
induced lung injury.19
The findings from the foregoing series of knockout and
rescue experiments showed that increased ACE activity me-
diates ALI, and ACE2 activity is protective. Investigators
inferred that therapeutic strategies that inhibit the RAS
would mitigate downstream elaboration of inflammatory
cytokines and ameliorate lung injury.20 A prospective study
of a lipopolysaccharide (LPS)-mediated lung injury model in
rats showed that pretreatment with enalapril, an ACE inhibi-
tor that inhibits ACE activity and increases serum ACE2
activity, reduced serum expression of proinflammatory cy-
tokines and reduced lung injury by LPS. Pretreatment with
enalapril suppressed nuclear factor kappa B (NF-κB), a down-
stream target of AT II in rats subjected to LPS-mediated lung
injury.
In rats subjected to LPS-induced lung injury and moderate
tidal volume mechanical ventilation, oxygenation was im-
proved in animals treated with losartan, an angiotensin
receptor blocker. Administration of cyclic Ang 1–7 also sig-
nificantly improved oxygenation in this animal model of lung
injury. Although earlier studies focused on serum levels of the
ACE and ACE2, Wösten-van Asperen et al21 showed that, in
bronchoalveolar lavage (BAL) fluid in rats with LPS- and
mechanical ventilation–induced ARDS, ACE activity was
higher and ACE2 activity was lower than in spontaneously
breathing animals. Similarly, AT II levels were higher and Ang
Fig. 1 Schematic representation of severe acute respiratory syndrome coronavirus (SARS CoV) infection mediating acute lung injury through
angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 2 (ACE2) signaling pathways. ACE converts angiotensin I (AT I) to
angiotensin II (AT II). AT II binds the angiotensin II receptor 1a (AT1aR), leading to tissue damage and lung edema, or it binds the angiotensin II
receptor 2 (AT2R) reducing tissue damage. ACE2 inactivates AT II, generating angiotensin 1–7 (AT 1–7). SARS CoV binds to ACE2 causing
downregulation of ACE2 through internalization of this membrane-bound protein and leading to viral replication in the cytoplasm. In this
illustration the virus is infecting a type II pneumocyte. Administration of recombinant ACE2 (rACE2) reduces lung damage by inactivating AT II.
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1–7 levels were lower in animals with ARDS than in sponta-
neously breathing animals. Although it was not statistically
significant, total protein in the BAL specimens of animals with
LPS-induced lung injury treated with either losartan or cyclic
Ang 1–7 tended to be lower. This finding suggests that treat-
ments aimed at blunting ACE signaling pathway activity or
enhancing the ACE2 signaling pathway may reduce inflam-
mation, lung injury, and the amount of protein that accumu-
lates in the alveoli.
Treml et al22 conducted a prospective, randomized, double-
blinded study of recombinant human ACE2 treatment in
piglets with LPS-induced ARDS. The animals were intubated,
mechanically ventilated, and had pulmonary artery catheters
placed prior to LPS-induced lung injury. This was a small study
with six piglets receiving sham normal saline infusion and six
animals receiving infusion of recombinant ACE2. Another
three animals served as negative controls and received no
LPS andno therapy. Thepiglets treatedwith recombinant ACE2
had higher partial PaO2 and a reduction in the mean pulmo-
nary artery pressure with unchanged wedge pressures. The
authors used inert gas elimination to evaluate ventilation and
perfusionmatching and found that pulmonary blood flowwas
more homogeneous in animals treatedwith ACE2. The authors
addressed the concern of lowering systemic blood pressure
with agents that inhibit the RAS by cleaving AT II. In control
animals, not exposed to LPS, treatment with ACE2 induced
hypotension and AT II levels were undetectable in these
animals. Animals with LPS-induced lung injury were found
to have an eightfold elevation in AT II. TreatmentwithACE2did
not result in AT II levels below basal levels and did not change
the blood pressure significantly.
Cytokine profiles that reflect the downstream signaling
effects of the disruption of the ACE and ACE2 balance have
been examined in lung samples obtained postmortem from
SARS victims, from African green monkeys, from macaques,
and from mice. Quantitative PCR analysis of postmortem
samples from SARS victims showed a variety of genes were
upregulated, including IL-8.23 In situ hybridization studies of
postmortem lung specimens using monoclonal antibodies
showed an elaboration of various proinflammatory cytokines
by ACE2-positive, SARS CoV–infected cells. MCP-1, TGF B1,
tumor necrosis-α (TNF-α), IL-1b and cardiotrophin-like cyto-
kine were upregulated in lungs and other organs of the SARS
patients. African green monkeys develop more severe lung
injury than macaques after SARS CoV infection and IL-6, IL-8,
CXCL1, CXCL2, are induced and upregulated only in African
green monkeys. These findings suggest that some of these
differentially expressed proinflammatory genes may be criti-
cal in the pathogenesis of severe lung injury induced by SARS
CoV infection.24 In summary, downstream signaling path-
ways activated by SARS CoV infection, mediated by ACE and
ACE2 activity, are not well understood but appear to reflect
nonspecific elaboration of proinflammatory cytokines.
Beyond postmortem studies of gross pathology and gene
expression studies from tissue samples from SARS victims, little
is known about the ACE/ACE2 pathway in ALI. Kharofa et al25
published results from a small retrospective study of 162
patients with stage I through III small cell and non–small cell
lung cancer who received radiation therapy within the Veterans
Affairs health care system between 2004 and 2009. The authors
found that the rate of grade 2 pneumonitis was significantly
lower in patients taking ACE inhibitors (2%) than in nonusers
(11%). The patients who self-reported ACE inhibitor use were
similar to those who did not use this class of medication with
respect to types and stages of cancer, radiation dosage, lung
volume irradiated, age, andconcurrent chemotherapy. This small
retrospective cohort study suggests that exposure to ACE in-
hibitors may reduce the risk of radiation pneumonitis.
Postmortem pathology studies and various in vitro and in
vivo model systems of SARS CoV infection suggest that the
virus enters through the respiratory tract and binds ACE2 in
the alveolar epithelium. Infection is followed by serological
evidence of increased ACE activity and decreased ACE2
activity. The signaling pathways that are activated by binding
the SARS CoV to ACE2 and the subsequent downstream
cytokine elaboration appear to share common features
with other mechanisms of ALI and result in a pathological
phenotype indistinguishable from other mechanisms of lung
injury. The animal models of ALI that are rescued by admin-
istration of intravenous or intraperitoneal agents to restore
the balance of ACE and ACE2 activity suggest that the vascular
endothelium is also involved in lung injury and that therapy
may be delivered systemically rather than to the alveolar
epithelium, the site of initial viral binding and infection. The
epidemiological features of persons at high risk of severe
infection and complications do not suggest a particular host
defect. It has been proposed that older individuals may
elaborate a more robust inflammatory response due to alter-
ations in the oxidative-stress machinery that come with age.
However, systemic corticosteroids administered to blunt the
downstream inflammatory cytokine elaboration were not
effective treatments for patients with SARS CoV infection.
The important downstream targets upregulated by ACE and
downregulated by ACE2 are not yet well understood. The
relative contributions of endothelial and epithelial processes
to the development of lung injury and the molecular path-
ways that link initial binding of the virus to alveolar cells with
the development of DAD are under active investigation. The
pathways involved in lung injury induced by SARS CoV
infection may be common to other mechanisms of injury,
including LPS, acid aspiration, and cecal ligation and perfora-
tion, and thereforemayprovide the framework for developing
a more universal therapy for lung injury mediated by other
infectious and noninfectious processes.
Background and Epidemiology of 2009
Pandemic H1N1 Influenza
Six years after the SARS global outbreak, the 2009 H1N1
influenza pandemic erupted and with it came a surge of
research investigating the mechanisms of lung injury that
develop in severe cases of H1N1 infection. Influenza viruses
belong to the family Orthomyoviridae, and are enveloped
negative-sense RNA viruses with segmented genomes. There
are three antigenically distinct subtypes, A, B, and C, which
circulate globally among human populations. Influenza A
Seminars in Respiratory and Critical Care Medicine Vol. 34 No. 4/2013
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viruses are subdivided based on antigenic characterization of
the surface glycoproteins hemagglutinin (HA) and neuramin-
idase (NA). There are 16 HA subtypes and nine NA subtypes.
Influenza is an acute respiratory disease that presents with
sudden onset of high fevers, chills, myalgias, upper respirato-
ry tract symptoms, and diarrhea. Infection rarely induces
symptoms of lower respiratory tract infections or severe lung
injury. Influenza virus infection has been a global health
concern since the 1918 Spanish flu pandemic. Three influen-
za pandemics occurred in the 20th century. The pandemics of
1918, 1957, and 1968 were caused by different antigenic
subtypes of influenza A: H1N1,H2N2, andH3N2, respectively.
InMarch 2009 a novel influenza virus emerged inMexico and
the United States and quickly spread worldwide. The pan-
demic A (H1N1) virus originated from the triple-reassort-
ment of swine influenza (H1) virus circulating in North
American pigs. On June 11, 2009, WHO declared a world
pandemic alert.26 By August 1, 2010, almost every country
had reported laboratory-confirmed cases, with over 18,449
deaths http://www.who.int/csr/don/2010_08_06/en/index.
html). A study of 642 cases from the early outbreak in the
United States found the most common presenting symptoms
were fever (94%), cough (92%), and sore throat (66%); 25% of
patients had diarrhea, and 25% had vomiting. Hospitalization
and mortality data were known for 399 of these cases and
showed a 9% hospitalization rate and a case fatality ratio of
0.5%.27 A study of 863 confirmed cases in Ontario, Canada,
showed similar presenting symptoms and a hospitalization
rate of 3.6% and a case fatality ratio of 0.2%.28
The 2009 pandemic H1N1 virus developed by reassort-
ment among several influenza A strains. Nucleic acid se-
quencing showed that the HA, nucleoprotein (NP), and
nonstructural protein (NS) gene segments were from the
classical swine viruses; PB1 gene segment from human
seasonal H3N2 influenza viruses; and PB2 and PA genes
from avian influenza viruses. NA and M gene segments
were genetically different from previously isolated human
pathogens and found to originate from Eurasian swine influ-
enza strains. Studies in ferrets and mice showed that, com-
pared with seasonal H1N1, intranasal inoculation with
pandemic H1N1 causes a higher morbidity, higher viral titers
in lung tissue, and viral shedding in the gastrointestinal tract,
suggesting amore invasive pathogen.29–31 Seasonal influenza
causes the highest mortality rates among older persons. In
contrast, the 2009H1N1pandemic affected young individuals
disproportionately.32
The majority of H1N1-infected patients were children or
adults aged < 60 years; most recovered uneventfully, and the
overall mortality was not higher than that of seasonal influ-
enza. Risk factors for more severe infection by pandemic
H1N1 include extremes of age, underlying medical illness,
obesity, and pregnancy.33–36 However, some previously
healthy patients without comorbidities developed rapidly
progressive pneumonia, ARDS, multiorgan failure, and death.
ARDS was reported to be the prominent cause of death.
Patients with more severe disease presented with fever,
cough, respiratory distress, bilateral patchy pneumonia, ele-
vated serum lactate dehydrogenase (LDH) and creatinine
kinase levels, and leukopenia. These features were common
to cohorts of adults and children studied worldwide.26,36–40
Findings from several epidemiological studies suggest that
pregnant women and obese individuals are more susceptible
to severe infection from pandemic H1N1, but the molecular
mechanisms underpinning these associations are not clear.
The relationship between obesity and the inflammatory
cascade responsible for ALI by various mechanisms is an
area of active research. Adipocytes and macrophages isolated
from obese patients secrete large quantities of proinflamma-
tory cytokines, including IL-6 and TNF-α. The release of these
factors into serum has been shown to contribute to the
development of both obesity-related metabolic and cardio-
vascular diseases. It has been hypothesized that this chronic
inflammation may also prime lung tissue for ALI.41 The
proinflammatory properties of lectin and anti-inflammatory
properties of adiponectin may also influence the risk of
developing ALI. Although epidemiological data from the
H1N1 pandemic suggest that obese patients are at higher
risk for ALI and have elevated levels of various inflammatory
cytokines, the cytokine profiles from sera collected from
ARDSNet participants showed that obese patients with ALI
induced by a variety of mechanisms had lower levels of
proinflammatory cytokines IL-6 and IL-8.42 This finding
suggests that the description of serum cytokines profiles
varies by disease state, and it is unlikely that cytokine profiles
are conserved among mechanisms of ALI from viral infec-
tions. Interestingly, the aforementioned study did find ele-
vated levels of surfactant proteinD (SP-D) andvonWillebrand
factor (vWF), markers for endothelial injury, in obese patients
with ALI. Epithelial injury may be less important than endo-
thelial disruption in some mechanisms of ALI. Recent studies
in obese mice showed that obesity is associated with neutro-
phil dysfunction and attenuates murine ALI in an LPS mod-
el.43 This study did not specifically investigate the role of the
endothelial compartment in murine ALI.
Treatment Recommendations Based on
Human Studies
Treatment of H1N1 infection is generally supportive. Most
patients infected with the virus experience typical influenza
symptoms and fully recover within aweek and do not require
antiviral therapy. Patients with severe illness or lower respi-
ratory symptoms should be treated with NA inhibitors:
oseltamivir, in most cases, or nebulized zanamivir or intrave-
nous peramivir if oseltamivir is not available. In cases of
severe illness, higher dosing of oseltamivir and longer dura-
tion of treatment may be considered.28
Although the authors of a prospective case series of 13
patients in Buenos Aires with ARDS and ALI presenting with
flu-like illness suggest that treatment with corticosteroids in
addition to NA inhibitors is safe, this is not the recommended
treatment strategy for severe H1N1 infection. Only eight
patients had PCR-confirmed H1N1, and the small size of
this study limits analysis of mortality differences.44 There
are no convincing data suggesting that the use of systemic
corticosteroids to treat severe H1N1 infection is beneficial.
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Corticosteroid use has been associatedwith poor outcomes in
other viral respiratory diseases. Early use of corticosteroids in
SARS and H3N2 influenza was associated with prolonged
periods of viral replication andmay have increased the rate of
secondary bacterial VAP.45–47
Recommendations for respiratory support of patients with
ARDS or ALI fromH1N1 are similar to thewidely accepted use
of lung-protective ventilation with lower tidal volume and a
fluid conservative strategy.48,49 Advanced supportive meas-
ures for refractory hypoxemia such as extracorporeal mem-
brane oxygenation (ECMO), high-frequency oscillation
ventilation, prone positioning, neuromuscular blockade,
and inhaled nitric oxide have been effective in ICUs with
expertise in these modalities.38,39,50 IVIG and N-acetyl-L-
cysteine have been used to treat infections by other influenza
subtypes, but their use has not been studied in H1N1
infection.28,51
Because themechanism of ALI inH1N1 infection is not well
understood, treatment for patients infected with pandemic
influenza A is largely supportive. Unraveling the molecular
underpinnings of viral replication and the host immune
response to infection may lead to targeted therapies or
immunomodulatory strategies that could be more broadly
applied to othermechanisms of ALI. Experimentswith animal
models have added some information about the cytokine
cascade and inflammatory response to infection, although
extrapolating these data to human infection is challenging
because the many competing animal models suggest that
there could be significant differences between species. Fur-
thermore, there are many different H1N1 strains used in
experimentalmodels, and these strains are all subject to fairly
rapid rates of mutations. Epidemiological studies summa-
rized following here provide little information about why
some patients develop more severe illness, characterized by
an inflammatory response to viral infection leading to ALI
with the most severe cases showing nonspecific pathological
findings of DAD with or without hemorrhage or necrotizing
bronchiolitis. The relationship of epithelial and endothelial
injury is not well understood, and experimental models do
not always distinguish between direct cytotoxic effects of
alveolar epithelial cell infection and host inflammatory re-
sponses that arise from endothelial injury and systemic,
circulating factors.
Human Studies Performed During the 2009
H1N1 Pandemic
Only a small minority of patients infected with pandemic
H1N1 go on to develop serious illness necessitating hospi-
talization or intensive care. The factors that mitigate the
more severe inflammatory host response are still unclear. A
study of sera from 57 patients in Hong Kong with H1N1
infection showed that T-helper 1 (Th1) and T-helper 17
(Th17) hypercytokinemia is an early host response in
severe 2009 H1N1 cases. A prospective analysis of cytokine
and chemokine profiles in sera from 35 patients in Spain
with H1N1 infection showed common expression patterns
of innate antiviral response proteins across patients with
mild illness and those with more severe presentations. All
35 subjects with H1N1 infection showed increased expres-
sion of chemokines CXCL10, CCL2, and CCL4. These chemo-
kines are also upregulated in SARS CoV, H5N1, and RSV
infection and are markers for innate immune response to
viral infections. The authors compared the serum cytokine
profiles of infected outpatients with those of patients with
noncritical respiratory insufficiency admitted to the hospi-
tal, and critically ill patients with respiratory insufficiency.
Patients with respiratory compromise had increased levels
of Th1 and Th17 cytokines when compared with healthy
individuals and outpatient controls. Critically ill patients
had elevated serum levels of IL-15, IL-12p70, and IL-6.
These proinflammatory cytokines stimulate the adaptive
immune response and may represent the pathological
difference between the host response to infection that
causes mild illness and those that result in severe systemic
inflammatory response.52
A study of 32 patients in Romania with H1N1, 21 with
ARDS and 11withmild disease, showed that severe influenza
A (H1N1) virus infectionwas characterized by IL-6, IL-15, IL-8,
and TNF-α.53 These cytokines, except TNF-α, had a positive
correlation with the admission delay and C-reactive protein,
and a negative correlation with the PaO2: FiO2 ratio. Of note,
in this study IL-17 levels were not elevated in patients with
severe disease. Interestingly, obese patients with pandemic
H1N1 infection have significantly higher levels of IL-8 than
infected nonobese patients. This finding differs from the
previously described results from Stapleton et al42 using
sera from ARDSNet patients, collected before the H1N1
pandemic.
Three distinct pulmonary histological patterns have been
described in autopsy studies of patients infected with pan-
demic H1N1; DAD, necrotizing bronchiolitis, and DAD with
intense pulmonary hemorrhage.54 Several case series found a
significant proportion of patients with severe H1N1 infection
had secondary bacterial pneumonia with Streptococcus,
Staphylococcus, and Haemophilus species, and a few cases
with multiple bacterial pathogens isolated.55,56 These autop-
sy studies show H1N1 results in a nonspecific final patholog-
ical pattern and may predispose to superimposed bacterial
infections. A recent cohort study by Rice et al57 found that
bacterial coinfection was common in patients infected with
pandemic H1N1 admitted to ARDSNet ICUs in North America.
Thirty percent of patients in this study had evidence of
bacterial coinfection, and of the patients with bacterial
infections, 11% had Staphylococcus aureus in blood or respi-
ratory cultures and 8% had Streptococcus pneumoniae. Human
studies from serum, BAL fluid, and autopsy specimens have
not shed much light on the molecular mechanisms involved
in H1N1-induced ALI. The clinical response to influenza
infection ranges from mild disease to severe pneumonia,
and it remains unclear whether the inflammatory response
to infection is protective or pathogenic. Experiments using a
variety of animal models have provided more detailed infor-
mation about the inflammatory response to infection and
some areas for investigations of potential therapeutic
strategies.
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Experimental Animal Models of 2009
Pandemic H1N1 Infection
Findings from animal models should be extrapolated to
human disease with caution. In the case of pandemic H1N1
influenza infection, it is important to recognize that research
groups use a variety of animal models and different viral
strains. Several viral isolates have been used by various
research groups to study H1N1 infection in mouse models,
including pandemic 2009 A/California/07/2009 (CA07), influ-
enza A/Puerto Rico/8/34 (PR8), and A/Beijing/501/2009
(BJ501).29,58,59 Furthermore, these strains are subject to
mutations, which may have important implications for data
interpretation. Several researchers have demonstrated viral
mutations in clinical and experimental strains that confer
higher virulence. For example, a substitution of glutamate by
glycine at position 222 of the viral hemagglutinin was found
to be significantly more frequent in patients with severe
pandemic influenza H1N1; furthermore other mutations
have been shown to confer higher virulence in mice.59–62 In
addition to mutations within a given strain, subtype varia-
tions also influence experimental findings. Although it is
tempting to extrapolate data from other viral subtypes to
pandemic H1N1 infection, this approach is misleading. How-
ever, Garigliany et al63 found that the two different influenza
A virus subtypes, H1N1 and H5N1, both evoked DAD as a final
pathological finding, and they were able to describe different
features within the DAD pattern. Interestingly, mice infected
with these viruses showed differences in courses of ARDS, and
blinded examination of histopathologic findings could dis-
tinguish different signature features. These findings suggest
that, although infection by these two viral subtypes ultimate-
ly results in the nonspecific finding of DAD, theremay not be a
conserved inflammatory pathway underlying all severe in-
fluenza infections. Selecting an appropriate animal model
that accurately reflects the human immune response to H1N1
infection and the development of lung injury has been
challenging. Models of the 2009 H1N1 pandemic flu have
been developed in mice, ferrets, guinea pigs, and nonhuman
primates. H1N1 strains have been adapted to infect thehost of
interest. Mouse models have generated the bulk of available
data on H1N1 infection.
Cytokine Signaling
Crowe et al observed that IL-17RA knockout mice recruited
fewer neutrophils to the airway in response to challenge with
either influenza A virus or hydrochloric acid and that this
decrease in neutrophils results in lower amounts of oxidized
phospholipids.64 IL-17 regulates neutrophil and Th1 cell re-
cruitment ligands. Furthermore, the IL-17RA knockout mice
had lower morbidity and mortality despite longer latency to
viral clearance and higher viral titers. The IL-17RA knockout
mice had less lung injury, as indicated by less total protein and
LDH activity in the BAL fluid and less severe inflammation on
histological examination. The differences in inflammation be-
tween wild-type and IL-17RA-deficient mice correlated well
with differences inmany inflammatory cytokines. Importantly,
TNF-α, IL-1β, and IL-6, three proinflammatory cytokines that
are generally elevated in severe influenza infection as part of a
cytokine storm, all either trended lower or were significantly
reduced in the IL-17RA / animals. These data support the
potential therapeutic manipulation of IL-17 or IL-17RA in ALI.
BAL fluids from 4-week-old B6 mice infected with BJ501
had similar cytokine and chemokine profiles to the human
sera samples in the studies of patients from Spain and Hong
Kong described earlier. Comparedwith wild-type B6mice, IL-
17-deficient mice infectedwith BJ501 had improved survival,
less weight loss, less leukocyte infiltration and therefore
lower lung injury scores, and decreased lung edema. Intrave-
nously administered anti-IL-17 antibodies also reduced dis-
ease severity.65 Similarly, Crowe et al showed that IL-17RA-
deficientmice had reducedweight loss and improved survival
after influenza infection.64 These data support the hypothesis
that IL-17 plays a critical role inmediating lung injury. IL-17 is
secreted by many cells, including Th17 cells, gamma delta T
cells, and natural killer (NK) cells. It acts as a proinflammatory
cytokine and links the innate and adaptive immune system by
recruiting neutrophils, it has a role in a variety of tissue injury
models, and it has been implicated in several disease pro-
cesses.66,67 A fully human monoclonal IL-17 antibody has
been developed by Novartis and clinical trials in Crohn
disease and rheumatoid arthritis are under way.
Airway Macrophages
Following intranasal infection of mice, influenza virus replicates
in type II epithelial cells lining the respiratory tract. Alveolar
macrophages, located at the interface between air and lung, are
mediators of the innate immune response and elaborate cyto-
kine responses that limit further replication of influenza virus.68
It is not clear whether influenza infection of macrophages is
abortive and viral progeny are not released, or if there is perhaps
limited release of H1N1 and H5N1 viruses from infected mouse
macrophages.69Despite similar abilities to infect urine epithelial
cells, virus strain BJx109 (H3N2) causes mild diseasewhile virus
strain PR8 (H1N1) causes severe disease. BJx109 infects murine
airwaymacrophageswith high efficiency,whereas PR8does not.
PR8 causes more severe disease than BJx109. In macrophage-
depleted mice, BJx109 causes severe disease, but the disease
severity of PR8 infection inmacrophage-depletedmice is similar
to untreated mice. Expression of the BJx109 HA on a PR8
backbone ameliorates severe disease.70 Collectively, these find-
ings suggest that internalization and nonproductive infection of
airway macrophages could be a critical factor in limiting severe
disease caused by influenza infection in mice.
Neutrophils
Data suggest that neutrophils play a key role in the develop-
ment of ALI after H1N1 infection and that the result of the
previously described cytokine elaboration is neutrophil re-
cruitment to the alveolar space. Several mouse models of
infection show results that are similar to the epidemiological
findings from the 2009 pandemic. Influenza A/swine/Shan-
dong/731/2009 (SD/09) is H1N1 with G222D mutation in the
HA. Mice infected with SD/09 developed ARDS and had a 60%
mortality rate between days 8 and 10 after infection. Mice
show neutrophil-predominant infiltrates in the BAL fluid.
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Serum IL-6 and TNF-α were elevated in SD/09 infected mice,
as were Il-10, IFN-gamma, and MCP-1.71
As already described, pregnant women are at higher riskof
developing severe H1N1 infection. Pregnant BALB/c mice
have a higher mortality, more severe pneumonitis, higher
pulmonary viral load, lower peripheral blood T lymphocytes
and antibody responses, higher levels of proinflammatory
cytokines and chemokines, andworse fetal development than
occurred in nonpregnant controls infected by either wild-
type (clinical isolate) or mouse-adapted mutant virus with
D222G substitution inHA. Comparedwith nonpregnantmice,
significantly higher levels of IL-1β, macrophage-inflammato-
ry protein (MIP)-1α, and MIP-2 were detected in pregnant
mice infected with wild-type virus (P < 0.03), whereas levels
of IL-6, MIP-1α, and MIP-2 were elevated significantly in
pregnant mice infected by mutant virus (P < 0.02). Notably,
level of IFN-γwas significantly lower in pregnant mice than in
nonpregnant mice (P < 0.05), whereas TNF-α level was simi-
lar between pregnant and nonpregnant mice, whether they
were infected by wild-type or mutant virus.59
Neutrophilic infiltrates have been observed in BAL fluid
and on pathology specimens from patients infected with
severe H1N1 infection leading to ARDS, but the mechanism
of alveolar damage has not been definitively worked out.
Neutrophils have a primary role in the innate immune system
through phagocytosis, secretion of reactive oxygen inter-
mediates, and formation of neutrophil extracellular traps
(NETs). Neutrophils emit their DNA fibers that carry nuclear
and cytoplasmic proteins and trap extracellular pathogens.
NETs attach to the capillary endothelium and are associated
with vasculitis and vascular damage in sepsis.
Macrophage-depleted mice infected with PR8 influenza A
H1N1 displayed enhanced viral replication, excessive neutro-
philic infiltration, alveolar damage, lung edema, and progres-
sion to ARDS.72 Neutrophil-depleted mice showed only mild
lung pathology after H1N1 infection. The authors noted
prominent NETs formation in lung tissue from the macro-
phage-depleted animals after H1N1 infection. NETs were also
present in normal mice treated with lethal doses of H1N1. In
vitro studies suggested that influenza infection enhances
NETs formation. Neutrophils incubated with influenza-
primed alveolar epithelial cells formed NETs. This particular
interaction between NETs and the endothelium could help
explain how epithelial and endothelial damage are related in
the development of ARDS in response to H1N1 infection.
As previously mentioned, there does not seem to be a
conserved pathologicalmechanism for lung injury induced by
different influenza subtypes. In an H3N2 murine model, Tate
et al showed that reduced numbers or impaired neutrophil
function facilitates progression of mild influenza to severe
clinical disease. Neutrophil depletion with monoclonal anti-
bodies was associated with more severe illness and lung
injury and enhanced viral replication in a murine model of
H3N2 infection.73,74
Endothelium
Many of the aforementioned studies do not specifically
distinguish between the mechanism of injury to alveolar
epithelium and the capillary endothelium. Much of the data
are based on serum cytokine levels that are not always
correlated with alveolar lavage samples. NETs provide one
possible explanation for how the inflammatory response in
both compartmentsmay be related. Interestingly, most of the
rescue therapies in murine models are administered intra-
peritoneally or intravenously. Effective systemic therapy
delivered hematogenously to the alveolus suggests that the
endothelium has an important role in cytokine and chemo-
kine signaling and generating the inflammatory host re-
sponse in severe influenza. Studies of H5N1 virus in
human microvascular endothelial cell cultures show viral
tropism for the apical surface and high infectivity.75 Similar
studies of H1N1 infection of monolayer cell culturemodels of
human pulmonary microvascular endothelial cells showed
increased expression of inflammatory cytokines Il-6, IL-8,
TNF-α, and interferon gamma-induced protein-10. This cy-
tokine expression was reduced by inhibiting pre–B cell
colony enhancing factor (a potential biomarker for ALI in
animal models).76 The sphingosine-1-phosphate (S1P) re-
ceptor is expressed in endothelial cells and lymphocytes
within the lung tissue. In mice, an S1P receptor antagonist
suppresses chemokine and cytokine production, including
IFN-α, CCL2, EL-6, TNF-α, and IFN-α after influenza infection.
The reduction in cytokine elaboration by S1P is associated
with decreased extravasation of leukocytes into the alveolar
space, but it does not decrease the recruitment of macro-
phages and NK cells after H1N1 infection.77 Suppressing the
adaptive immune response was associated with improved
mortality. Collectively, these data suggest that endothelial
cells orchestrate the distinct events of immune cell infiltra-
tion and cytokine production following H1N1 infection in
mice.
Current and Potential Therapeutic Strategies
Supportive measures including lung protective ventilation
and NA inhibitors are the mainstay of therapy for severe
influenza infection, resulting in respiratory failure and ALI.
Monoclonal antibodies and vaccines directed at conserved
regions between influenza strains are areas of ongoing in-
vestigation. IL-17 is another target for potential monoclonal
antibody therapy. Corticosteroids are not currently recom-
mended and may be harmful.78,79 Investigations of general-
ized anti-inflammatory therapy are under way. For example,
a combination of caffeine and a statin ameliorated lung injury
and viral replication in BALB/c mice infected with H5N1,
H3N2, and H1N1.79 Targeted nucleic acid therapy is also
being studied. Fang et al explored a microsatellite DNA
mimicking oligodeoxynucleotides (MS ODN) for the treat-
ment of H1N1 infection. On days 2 and 4 postinfection with
influenza A/FM/1/47 virus (H1N1), mice were injected with
MS ODN named SAT05f. This MS ODN is capable of inhibiting
Toll-like receptors 7 and 9. The MS ODN treatment improved
survival, less histopathological changes with fewer neutro-
phils per high-power field, and reduced levels of TNF-α in
lung homogenates.
When investigating therapeutic strategies, it is important
to consider if it is practical to expect an intervention can be
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made before significant lung injury develops in patients
infected with H1N1, or any viral pneumonia for that matter.
Although it is possible that earlier identification of patients
before they require positive pressure ventilation in what is
now termed early ALI might facilitate efficacy of future
therapies.80
In addition, future strategies will need to focus on mech-
anisms that might enhance repair. The use of stem cells and
stem cell–derived growth factors may become an important
therapeutic intervention for patients with ALI and ARDS,
independent of the mechanisms of initial injury.81
Conclusions
The lessons learned from studying pandemic outbreaks of
SARS CoV and H1N1 capture some key principles of virally
mediated ALI. There appear to be several pathogen-specific
pathways underlying virally mediated ALI that converge
onto a common end pathway resulting in DAD. It remains to
be determined whether alveolar epithelial injury is the
primary lesion or is coincident to lung endothelial injury.
There also seems to be an interaction of viral infection with
the microbiome of the lung that might predispose patients
with viral pneumonia to secondary bacterial and fungal
pneumonia. Therapeutic strategies may be targeted to
specific pathogens or common pathways in the host im-
mune response. Alternatively, perhaps it would be most
advantageous to investigate lung repair strategies that rely
less on a complete understanding of the complicated virus–
host interaction and more on repairing the final common
pathway of DAD. These repair strategies may provide treat-
ments for all virally mediated lung injury as well as ALI
sustained from a variety of other insults.82 Scientists spec-
ulate that many influenza viruses, including H5N1, are
capable of causing a pandemic in the near future.83 The
looming threat of the next outbreak of a pandemic respira-
tory viral infection makes a compelling argument for the
continuation of investigations into the host immune re-
sponse to viral infection in the lung, better antiviral thera-
pies, and research targeting the fundamental strategies to
enhance lung repair from virally mediated ALI.
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